-
公开(公告)号：US11981734B2
公开(公告)日：2024-05-14
申请号：US17668807
申请日：2022-02-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC: C07K16/28 , A61K39/395 , A61K47/68 , A61P35/00 , C07K1/22 , C12N5/071 , C12N15/85 , C12P21/00 , G01N33/68 , A61K39/00
CPC classification number: C07K16/2803 , A61K39/3955 , A61K47/6849 , A61P35/00 , C07K1/22 , C12N5/0682 , C12N15/85 , C12P21/005 , G01N33/68 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N2510/02 , C12N2800/107
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
Patent Agency Ranking
公开(公告)号：US20220204618A1
公开(公告)日：2022-06-30
申请号：US17670398
申请日：2022-02-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC: C07K16/28 , A61K39/395 , A61P35/00
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US12077584B2
公开(公告)日：2024-09-03
申请号：US17670398
申请日：2022-02-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC: C07K16/28 , A61K39/00 , A61K39/395 , A61K47/68 , A61P35/00 , C07K1/22 , C12N5/071 , C12N15/85 , C12P21/00 , G01N33/68
CPC classification number: C07K16/2803 , A61K39/3955 , A61K47/6849 , A61P35/00 , C07K1/22 , C12N5/0682 , C12N15/85 , C12P21/005 , G01N33/68 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N2510/02 , C12N2800/107
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US11274150B2
公开(公告)日：2022-03-15
申请号：US16683927
申请日：2019-11-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US20230119066A1
公开(公告)日：2023-04-20
申请号：US17914257
申请日：2021-03-22
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Ruth Yin-Zong Lan , Olufemi A. Adelakun , Ishita Barman , Joseph Campbell , SJ Jian Zhe Diong , Felix Findeisen , Danielle M. Greenawalt , Renu Jain , Amy D. Jhatakia , John K. Lee , Peter S.K. Lee , Linda Liang , Kai Lu , Bryan McDonald , Paul Mesko , Arvind Rajpal , Sharmila Sambanthamoorthy , Mark J. Selby , Nathan O. Siemers , Pavel Strop , Gaby A. Terracina , Xi-Tao Wang
Abstract: This disclosure provides isolated antibodies, for example, monoclonal antibodies, that specifically bind to the C-C Motif Chemokine Receptor 8 (CCR8) expressed on the surface of a cell and mediate depletion of the CCR8-expressing cell by anti-body-dependent cellular cytotoxicity (ADCC). The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CCR8 antibody as monotherapy or in combination with an anti-cancer agent such as an immune checkpoint inhibitor, for example, an anti-PD-1 or anti-PD-L1 antibody.
-
公开(公告)号：US20220195042A1
公开(公告)日：2022-06-23
申请号：US17668807
申请日：2022-02-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikan Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger G. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
-
-
-
-
Search Results
6
records
(took 0.017 seconds)
